Ophthotech DRC Phase 2 OPH2007 - A Phase 2A Open-Label Trial to ASSESS the Safety of Zimura¿ (anti-c5) Administered in Combination With Lucentis® 0.5 mg in Treatment naive subjecTs with Neovascular Age related macular degeneration

Administered By

Awarded By

Contributors

Start/End

  • August 6, 2018 - May 28, 2019